Drug intelligence / Profile preview

Trivalent Influenza Virus Vaccine (TIVf)

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TIVf is a Trivalent Influenza Virus Vaccine, specifically a purified surface antigen, inactivated, and egg-derived formulation. It is developed for seasonal influenza prevention and is designed to evaluate safety, clinical tolerability, and immunogenicity in adults. The vaccine aims to induce an antibody response against the influenza vaccine antigens, measured by methods such as hemagglutination inhibition (HI) and single radial hemolysis (SRH). Its development and use are subject to yearly licensing requirements, particularly in compliance with European Union (EU) guidelines.

Beyond the preview

Go deeper on Trivalent Influenza Virus Vaccine (TIVf).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trivalent Influenza Virus Vaccine (TIVf).

Explore the full profile